Protein–Protein Interaction Modulators for Epigenetic Therapies
Abstract
Targeting protein-protein interactions (PPIs) is becoming an attractive approach for drug discovery. This is particularly true for difficult or emerging targets, such as epitargets that may be elusive to drugs that fall into the traditional chemical space. The chemical nature of the PPIs makes attractive the use of peptides or peptidomimetics to selectively modulate such interactions. Despite the fact peptide-based drug discovery has been challenging, the use of peptides as leads compounds for drug discovery is still a valid strategy. This chapter discusses the current status of PPIs in epigenetic drug discovery. A special emphasis is made on peptides and peptide-like compounds as potential drug candidates.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Undruggable proteins possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins; these networks have been considered undruggable biological processes for decades.
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [311]
The citation lists haven’t been fetched yet
References 74 · Cited by 31
- Authors
- Díaz‐Eufracio, B. I., Naveja, J. J., & Medina‐Franco, J. L.
- Affiliations
- Universidad Nacional Autónoma de México (MX)
- Corresponding author
- José L. Medina‐Franco
- Venue
- Advances in Protein Chemistry and Structural Biology
- Publisher
- Elsevier
- Published
- 2018
- Volume
- 110
- Pages
- 65-84
- ISSN
- 1876-1623 (ISSN-L)
- OpenAlex
- W2737953029
- Cited by
- 31
- References
- 74
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 6 · 2022: 5 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 1
- FWCI
- 4.42
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Advances in protein chemistry and structural biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Universidad Nacional Autónoma de México (PAIP 5000-9163, PAPIIT IA204016)
- Consejo Nacional de Ciencia y Tecnología (620289, 622969)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- protein-protein interaction, epigenetic drug discovery, peptides, peptidomimetics, peptide-based drug discovery, drug candidates, epigenetic therapy
- MeSH terms
- Humans, Peptides, Protein Binding, Proteins, Epigenesis, Genetic, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review